Growth hormone secretagogue Phase III trial is discontinued after mixed efficacy results from an October interim analysis. The trial, begun early in 1998, was in pediatric growth hormone deficient patients; development of MK-677 is also stalled for other populations such as the elderly, the company said
You may also be interested in...
Pfizer expects Relpax (eletriptan) to be the first triptan to receive a labeling claim for relief of menstrually-associated migraines.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011